Name | Value |
---|---|
Revenues | 2,737.0K |
Cost of Revenue | 1,535.0K |
Gross Profit | 1,202.0K |
Operating Expense | 1,759.0K |
Operating I/L | -557.0K |
Other Income/Expense | -1,444.0K |
Interest Income | 0.0K |
Pretax | -2,001.0K |
Income Tax Expense | -145.0K |
Net Income/Loss | -1,856.0K |
ThermoGenesis Holdings, Inc. develops and markets automated technologies for cell-based therapies, including the CAR-TXpress platform for CAR-T immunotherapy. Its suite of solutions includes the AXP II Automated Cell Separation System, BioArchive Automated Cryopreservation System, PXP Point-of-Care System, and X-Series products for cell isolation and purification. These products cater to clinical biobanking, point-of-care applications, and immuno-oncology, addressing the critical unmet need for large-scale cellular processing. The company generates revenue through the sale of its automated systems and platforms, which streamline the manufacturing process for cell-based therapies and contribute to advancements in the emerging CAR-T immunotherapy market.